BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

733 related articles for article (PubMed ID: 27313272)

  • 21. Practical utility of amyloid and FDG-PET in an academic dementia center.
    Sánchez-Juan P; Ghosh PM; Hagen J; Gesierich B; Henry M; Grinberg LT; O'Neil JP; Janabi M; Huang EJ; Trojanowski JQ; Vinters HV; Gorno-Tempini M; Seeley WW; Boxer AL; Rosen HJ; Kramer JH; Miller BL; Jagust WJ; Rabinovici GD
    Neurology; 2014 Jan; 82(3):230-8. PubMed ID: 24353340
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dual-biomarker imaging of regional cerebral amyloid load and neuronal activity in dementia with PET and 11C-labeled Pittsburgh compound B.
    Meyer PT; Hellwig S; Amtage F; Rottenburger C; Sahm U; Reuland P; Weber WA; Hüll M
    J Nucl Med; 2011 Mar; 52(3):393-400. PubMed ID: 21321269
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of 10-minute post-injection 11C-PiB PET and its correlation with 18F-FDG PET in older adults who are cognitively healthy, mildly impaired, or with probable Alzheimer's disease.
    Carneiro CG; Faria DP; Coutinho AM; Ono CR; Duran FLS; da Costa NA; Garcez AT; da Silveira PS; Forlenza OV; Brucki SMD; Nitrini R; Busatto G; Buchpiguel CA
    Braz J Psychiatry; 2022 Aug; 44(5):495-506. PubMed ID: 36420910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical impact of (11)C-Pittsburgh compound-B positron emission tomography carried out in addition to magnetic resonance imaging and single-photon emission computed tomography on the diagnosis of Alzheimer's disease in patients with dementia and mild cognitive impairment.
    Omachi Y; Ito K; Arima K; Matsuda H; Nakata Y; Sakata M; Sato N; Nakagome K; Motohashi N
    Psychiatry Clin Neurosci; 2015 Dec; 69(12):741-51. PubMed ID: 26085054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-modality molecular imaging characteristics of dementia with Lewy bodies.
    Gao ZB; Wang W; Zhao XL; Chen T; Fu LP; Xu BX; Wang ZF
    J Int Med Res; 2018 Jun; 46(6):2317-2326. PubMed ID: 29619853
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Amyloid imaging in dementias with atypical presentation.
    Wolk DA; Price JC; Madeira C; Saxton JA; Snitz BE; Lopez OL; Mathis CA; Klunk WE; DeKosky ST
    Alzheimers Dement; 2012 Sep; 8(5):389-98. PubMed ID: 22285638
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparisons of clinical symptoms in biomarker-confirmed Alzheimer's disease, dementia with Lewy bodies, and frontotemporal dementia patients in a local memory clinic.
    Shea YF; Ha J; Chu LW
    Psychogeriatrics; 2015 Dec; 15(4):235-41. PubMed ID: 25533477
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imaging beta-amyloid burden in aging and dementia.
    Rowe CC; Ng S; Ackermann U; Gong SJ; Pike K; Savage G; Cowie TF; Dickinson KL; Maruff P; Darby D; Smith C; Woodward M; Merory J; Tochon-Danguy H; O'Keefe G; Klunk WE; Mathis CA; Price JC; Masters CL; Villemagne VL
    Neurology; 2007 May; 68(20):1718-25. PubMed ID: 17502554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnostic role of 11C-Pittsburgh compound B retention patterns and glucose metabolism by fluorine-18-fluorodeoxyglucose PET/CT in amnestic and nonamnestic mild cognitive impairment patients.
    Jiménez-Bonilla JF; Banzo I; De Arcocha-Torres M; Quirce R; Martínez-Rodríguez I; Lavado-Pérez C; Bravo-Ferrer Z; Rodríguez-Rodríguez E; Sánchez-Juan P; Carril JM
    Nucl Med Commun; 2016 Nov; 37(11):1189-96. PubMed ID: 27341411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The value of multimodal imaging with
    Miyagawa T; Przybelski SA; Maltais D; Min HK; Jordan L; Lesnick TG; Chen Q; Graff-Radford J; Jones D; Savica R; Knopman D; Petersen R; Kremers WK; Forsberg LK; Fields JA; Ferman TJ; Allen L; Parisi J; Reichard RR; Murray M; Dickson D; Boeve BF; Kantarci K; Lowe VJ
    Neurobiol Aging; 2021 Mar; 99():11-18. PubMed ID: 33422890
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PET imaging of brain amyloid in dementia: a review.
    Quigley H; Colloby SJ; O'Brien JT
    Int J Geriatr Psychiatry; 2011 Oct; 26(10):991-9. PubMed ID: 21905095
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [11C]PIB binding in Parkinson's disease dementia.
    Maetzler W; Reimold M; Liepelt I; Solbach C; Leyhe T; Schweitzer K; Eschweiler GW; Mittelbronn M; Gaenslen A; Uebele M; Reischl G; Gasser T; Machulla HJ; Bares R; Berg D
    Neuroimage; 2008 Feb; 39(3):1027-33. PubMed ID: 18035558
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Utility of Molecular and Structural Brain Imaging to Predict Progression from Mild Cognitive Impairment to Dementia.
    Lan MJ; Ogden RT; Kumar D; Stern Y; Parsey RV; Pelton GH; Rubin-Falcone H; Pradhaban G; Zanderigo F; Miller JM; Mann JJ; Devanand DP
    J Alzheimers Dis; 2017; 60(3):939-947. PubMed ID: 28984586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of Early-Phase 11C-Deuterium-l-Deprenyl and 11C-Pittsburgh Compound B PET for Assessing Brain Perfusion in Alzheimer Disease.
    Rodriguez-Vieitez E; Carter SF; Chiotis K; Saint-Aubert L; Leuzy A; Schöll M; Almkvist O; Wall A; Långström B; Nordberg A
    J Nucl Med; 2016 Jul; 57(7):1071-7. PubMed ID: 26912447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships between biomarkers in aging and dementia.
    Jagust WJ; Landau SM; Shaw LM; Trojanowski JQ; Koeppe RA; Reiman EM; Foster NL; Petersen RC; Weiner MW; Price JC; Mathis CA;
    Neurology; 2009 Oct; 73(15):1193-9. PubMed ID: 19822868
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular imaging with Pittsburgh Compound B confirmed at autopsy: a case report.
    Bacskai BJ; Frosch MP; Freeman SH; Raymond SB; Augustinack JC; Johnson KA; Irizarry MC; Klunk WE; Mathis CA; Dekosky ST; Greenberg SM; Hyman BT; Growdon JH
    Arch Neurol; 2007 Mar; 64(3):431-4. PubMed ID: 17353389
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Early [(18)F]florbetaben and [(11)C]PiB PET images are a surrogate biomarker of neuronal injury in Alzheimer's disease.
    Tiepolt S; Hesse S; Patt M; Luthardt J; Schroeter ML; Hoffmann KT; Weise D; Gertz HJ; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Aug; 43(9):1700-9. PubMed ID: 27026271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regional analysis of FDG and PIB-PET images in normal aging, mild cognitive impairment, and Alzheimer's disease.
    Li Y; Rinne JO; Mosconi L; Pirraglia E; Rusinek H; DeSanti S; Kemppainen N; Någren K; Kim BC; Tsui W; de Leon MJ
    Eur J Nucl Med Mol Imaging; 2008 Dec; 35(12):2169-81. PubMed ID: 18566819
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biological characters of [18F]O-FEt-PIB in a rat model of Alzheimer's disease using micro-PET imaging.
    Zheng MQ; Yin DZ; Zhang L; Lei B; Cheng DF; Cai HC; Han YJ; Wu MX; Zhang H; Wang J
    Acta Pharmacol Sin; 2008 May; 29(5):548-54. PubMed ID: 18430362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 11C-PIB PET imaging in Alzheimer disease and frontotemporal lobar degeneration.
    Rabinovici GD; Furst AJ; O'Neil JP; Racine CA; Mormino EC; Baker SL; Chetty S; Patel P; Pagliaro TA; Klunk WE; Mathis CA; Rosen HJ; Miller BL; Jagust WJ
    Neurology; 2007 Apr; 68(15):1205-12. PubMed ID: 17420404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.